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Abstract
Purpose: To assess the use of temporal artery biopsy (TAB) in diagnosing giant cell
arteritis (GCA) and to evaluate patients’ clinical and laboratory characteristics.
Methods: We conducted a retrospective chart review of patients with suspected GCA
who underwent TAB and had complete workup in a tertiary center in Iran between 2008
and 2017. The 2016 American College of Rheumatology (ACR) revised criteria for early
diagnosis of GCA were used for each patient for inclusion in this study.
Results: The mean age of the 114 patients in this study was 65.54 ± 10.17 years. The
mean overall score according to the 2016 ACR revised criteria was 4.17 ± 1.39, with 5.82
± 1.28 for positive biopsies and 3.88 ± 1.19 for negative biopsies (p <0.001). Seventeen
patients (14.9%) had a positive biopsy. Although the mean post-fixation specimen length
in the biopsy-positive group (18.35± 6.9mm) was longer than that in the biopsy-negative
group (15.62 ± 8.4 mm), the difference was not statistically significant (P = 0.21). There
was no statistically significant difference between the groups in terms of sex, serum
hemoglobin, platelet count, and erythrocyte sedimentation rate. There were statistically
significant differences between the biopsy-negative and biopsy-positive groups with
respect to patients’ age and C-reactive protein level (P < 001 and P = 0.012, respectively).
Conclusion: The majority of TABs were negative. Reducing the number of redundant
biopsies is necessary to decrease workload and use of medical services. We suggest
that the diagnosis of GCA should be dependent on clinical suspicion.
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Giant cell arteritis (GCA) is a systemic immune-
related vasculitis involving medium- and
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large-sized arteries, especially of the carotid
branches, including the superficial temporal, oph-
thalmic, posterior ciliary, and occipital arteries.[1, 2]
The inflammation of the arterial wall causes luminal
obstruction and tissue ischemia.[3] The involvement
of these vessels can cause visual impairment or
loss. Vision loss in GCA is usually due to arteritic
anterior ischemic optic neuropathy, which is optic
nerve head ischemia caused by inflammation of the
wall of the posterior ciliary arteries.[1]
Correct diagnosis and urgent treatment with
systemic corticosteroids are necessary to prevent
major ischemic complications.[4] Although there is
no single test for diagnosing GCA, the American
College of Rheumatology (ACR) 1990 GCA classi-
fication criteria can assist in the diagnosis of sus-
pected cases.[5] The presence of at least three of
these five criteria carries a sensitivity of 93.5% and
a specificity of 91.2% for GCA.[5, 6] In 2016, a new
and more extensive set of criteria for early diagno-
sis of the GCA was proposed.[7] Table 1 shows the
2016 revised ACR (rACR) criteria for early diagnosis
of GCA (previously called temporal arteritis). It has
been suggested that in the presence of at least 3
out of 11 points, with at least one point belonging to
domain I, a diagnosis of GCA can be made.
Temporal artery biopsy (TAB) is indicated for
diagnosing suspected GCA cases.[8] Although the
value of TAB has been recently disputed because
of its high false-negative rates, it remains the gold
standard for diagnosis.[9]
The purpose of the current study was to investi-
gate the use of TAB in diagnosing GCA at a tertiary
center in Iran over a 10-year period. We investi-
gated and discussed the clinical and laboratory
results of patients with TAB-proven GCA and TAB-
negative cases according to the ACR criteria.
METHODS
We conducted a retrospective chart review in the
Neuro-ophthalmology Clinic at the Rassoul Akram
Hospital, a tertiary referral center in Tehran, Iran,
between 2008 and 2017. The study was approved
by the Ethics Committee of the Iran University
of Medical Sciences and adhered to the tenets
of the Declaration of Helsinki. We reviewed the
medical records of patients with suspected GCA,
including pathology reports of all TABs within this
period. The 2016 rACR criteria for early diagnosis
of giant cell (temporal) arteritis were considered for
each patient for inclusion in this study. The age-
specific maximal normal erythrocyte sedimentation
rate (ESR) was calculated according to the following
formulas: age in years/2 for men and (age in years
+10)/2 for women.[10] Superficial TABs (STABs) were
performed under local anesthesia using routine
surgical techniques by either ophthalmology, vas-
cular surgery, or neurosurgery residents with a
wide spectrum of surgical expertise.[11] The spec-
imens were fixed in 10% formalin. The lengths of
the formalin-fixed STAB samples on macroscopic
examination were included in the reports. The
specimens were processed using standard proto-
cols for embedding tissue in paraffin wax blocks.
The specimens were completely embedded, and
histopathological sections were cut at three or
more levels and examined after hematoxylin and
eosin staining. All patients had undergone TAB
within 1–2 days after starting steroid treatment.
The checklist information for each patient
included age, sex, laboratory test results
(hemoglobin, platelet count, ESR, and C-reactive
protein [CRP] levels), post-fixation STAB length,
histological findings, side of biopsy, and notes
of the ophthalmology team. Histological findings
were documented with respect to the presence
of multinucleated giant cells of Langerhans,
inflammatory cell infiltration, intimal proliferation,
and fragmentation of the internal elastic lamina.
Details on the exact number of sections and levels
examined were documented in most reports.
Some of the cases were excluded for having an
inappropriate biopsy specimen. All patients in the
TAB-positive group had leukocyte infiltration (one
point based on the rACR) and granuloma (one
point based on the rACR) in their histopathology
specimens.
Statistical Analysis
SPSS software version 22.0 (IBM Corp., Armonk,
NY) was used for statistical analyses. The Student’s
t-test was used for analyzing quantitative variables,
and the Chi square test was used for qualitative
variables. Results are reported as mean ± stan-
dard deviation. P values < 0.05 were considered
statistically significant. Statistical analysis was also
performed to compare the first and second five
years due to variation in specialties performing
the biopsies and differences in the TAB specimen
length over 10 years.
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Table 1. The 2016 revised ACR criteria for the diagnosis of GCA𝑎
Score Entry
N/A Age at onset ≥ 50 years
Absence of exclusion criteria𝑏
Domain I
1 New-onset localized headache,𝑐 1 point (p)
1 Sudden onset of visual disturbance,𝑐 1 point
2 Polymyalgia rheumatica, 2 points
1 Jaw claudication,𝑐 1 point
2 Abnormal temporal artery,𝑑 up to 2 points
Domain II
1 Unexplained fever and/or anemia, 1 point
1 ESR ≥ 50 mm/hour,𝑒 1 point
2 Compatible pathology,𝑓 up to 2 points
ACR, American College of Rheumatology; ESR, erythrocyte sedimentation rate; GCA, giant cell arteritis; N/A, not applicable
𝑎In the presence of three points or more out of the eleven with at least one point belonging to domain I along with all entry
criteria, a diagnosis of GCA can be established.
𝑏The exclusion criteria included ear, nose, and throat or/and eye inflammation; kidney, skin, or peripheral nervous system
involvement; lung infiltration; lymphadenopathies; stiff neck; and digital gangrene or ulceration.
𝑐No other etiologies can better explain any one of the criteria.
𝑑Enlarged and/or pulseless temporal artery (one point)/tender temporal artery (one point).
𝑒It must be ignored in the presence of polymyalgia rheumatica.
𝑓Vascular and/or perivascular fibrinoid necrosis along with leucocyte infiltration (one point) and granuloma (one point).
Table 2. Comparison between TAB-negative and TAB-positive patients according to the 2016 revised ACR criteria
TAB-positive (n = 17) TAB-negative (n = 97) P-value
ESR (mm/hour) 52.50 ± 33.28 52.30 ± 28.21 0.98
Hemoglobin (g/dl) 12.40 ±1.95 11.97 ± 1.80 0.38
Age (years) 75.66 ± 8.32 63.92 ± 9.51 < 0.001
Temporal tenderness 29.41% 35.05% 0.61
Jaw claudication 41.2% 26.8% 0.45
Pulseless temporal artery 17.64% 10.30% 0.26
ACR, American College of Rheumatology; ESR, erythrocyte sedimentation rate; TAB, temporal artery biopsy
RESULTS
In the primary collection of patient records, 257
patient charts were reviewed and analyzed. The
patients who lacked the 2016 rACR criteria, an
appropriate biopsy report, or the associated blood
test results were excluded. After also exclud-
ing patients with incomplete medical records, 114
patients with complete required information in
their charts who met the 2016 rACR criteria were
evaluated. Of these, 43 patients (37.7%) were male
and 71 (62.3%) were female, with an overall mean
age of 65.54 ± 10.17 years at the time of biopsy.
Of the 114 biopsies included in the study, 17 (14.9%)
showed the characteristics of GCA. The mean age
of TAB-negative patients [Figure 1] was 63.92± 9.51
years compared to a mean age of 75.66 ± 8.32
years in TAB-positive cases [Figure 2] (P < 0.001).
In patients with positive biopsies, the mean CRP
level was 30.50 ± 32.35 mg/L, whereas in those
with negative biopsies, it was 13.68 ± 18.91 mg/L (P
= 0.009). An abnormal ESR and ESR > 50 mm/hour
were present in 61% and 44% of cases, respectively.
The mean overall score according to the 2016 ACR
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Table 3. Comparison of the first and second five years in terms of biopsy result and length
Biopsy year Number of biopsies Biopsy result P-value Biopsy length (mm) P-value
Negative Positive
First five years 59 53 6 0.06 14.94 ± 9.25 0.03
Second five years 47 36 11 17.42 ± 6.88
revised criteria was 4.17 ± 1.39, with 5.82 ± 1.28
for positive biopsies and 3.88 ± 1.19 for negative
biopsies (p < 0.001).
Although the mean post-fixation specimen
length in the biopsy-positive group (18.35 ±
6.9 mm) was longer than that in the biopsy-
negative group (15.62 ± 8.4 mm), the difference
was not statistically significant (P = 0.21). Of the
114 patients, 96 cases presented with acute
visual loss; 83 (86.4%) of them had anterior
ischemic optic neuropathy (69 subjects in the
TAB-negative group and 14 in the TAB-positive
group); 8 (8.3%) were diagnosed with posterior
ischemic optic neuropathy (seven cases in the
TAB-negative group and one in the TAB-positive
group); and 5 (5.2%) cases had central retinal
artery occlusion (four cases in the TAB-negative
group and one in the TAB-positive group). Three
other patients developed acute cranial nerve
palsies; two patients had sudden third nerve palsy,
and one case presented with acute sixth nerve
palsy.
Table 2 compares the TAB-positive and TAB-
negative groups in terms of 2016 rACR scoring.
Except for age, there was no significant difference
between the biopsy-positive and biopsy-negative
groups in terms of their symptoms (all P-values >
0.05).
We also compared the results of first and second
five years to evaluate the human factor effect
during this time period [Table 3]. We observed
a significant increase in the specimen length
obtained during the second five years (P = 0.03)
but nonsignificant rise in the number of positive
biopsies (odds ratio = 2.69, P = 0.06).
DISCUSSION
This study describes the results of a cohort of 114
patients who met the 2016 rACR criteria for the
diagnosis of GCA and underwent TAB over a 10-
year period in a tertiary center in Tehran, Iran. We
aimed to evaluate the results of biopsies as well as
clinical and laboratory features of suspected GCA.
Although the overall mean age at biopsy in our
patients was 65.5 years, we observed a signifi-
cantly higher mean age in TAB-positive patients
than that in TAB-negative ones (75.6 compared to
63.9 years). This finding reflects the increase in
GCA incidence with age.
There is controversy regarding the impact of
the length of biopsy on the results of TAB. Table
4 summarizes the characteristics of previously
published studies about the association between
TAB length and its diagnostic yield. Due to the
probability of the presence of skip lesions, particu-
larly in cases with insufficient specimen size, false-
negative results (15–29%) may occur.[12] Ashton-Key
and Gallagher found 10–61% false negativity and
6% false positivity in TABs due to arteriosclerosis
as a result of aging and not the inflammatory
process.[13]
The ESR and CRP levels are biochemical mark-
ers that increase in GCA.We found a nonsignificant
difference in the mean ESR between cases with a
positive and those with a negative biopsy, but there
was a statistically significant higher CRP level in
the group of patients with a positive TAB than in
the group with a negative TAB. However, no score
has been considered for CRP according to the 2016
rACR criteria for the diagnosis of GCA.
The 1990 ACR diagnostic criteria for GCA
consists of age at disease onset of 50 years
or older, new headache, temporal artery abnor-
mality, elevated ESR, and abnormal TAB. Omit-
ting the biopsy item from the 1990 ACR score
leaves only four criteria, which makes it diffi-
cult to justify not performing TAB for low- or
high-risk patients. The applicability of the 1990
ACR criteria for the diagnosis of GCA according
to its symptoms is another challenging issue.
Murchison et al challenged the 1990 ACR criteria
for the diagnosis of GCA.[14] They found that
nearly 25% of the patients with positive TABs
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Table 4. Previous studies on the length of superficial temporal artery biopsy (STAB)















132 132 7.9 64 Size of 7 mm is
recommended for more
accurate results
Kent et al[24] 1990 USA Retrospective
review
70 73 N/S 11.4 Generous biopsy of ∼5 cm
of fresh vessel
recommended to confirm
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minimum threshold length
did not yield a statistically
significant difference in
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Mahr et al[29] 2006 France Retrospective
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were 2.8 times more likely
to show features of GCA









2011 UK Cohort 966 966 10 21.4 A 10-mm sample is
satisfactory (post-fixation
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length and results; hence
post-fixation length of 6
mm is satisfactory (biopsy
length >10 mm)
Au et al[4] 2016 Australia Retrospective
observational













715 715 11.64 ± 6.4 35 Length of specimen does
not necessarily change






116 116 9.4 55.2 TAB length is not
associated with the TAB
diagnostic yield in patients
with clinical suspicion of
GCA
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Table 4. Continued.















538 538 17.6 ± 9.1 23.4 Biopsy length of ≥
15 mm is
suggested
Current study 2019 Iran Retrospective
analysis








GCA, giant cell arteritis; N/S, not stated; TAB, temporal artery biopsy
𝑎Rate of positive biopsies in all biopsies
Figure 1. Histopathology section of a negative temporal artery biopsy. Note the intact lamina elasticum (short arrows) and the
absence of inflammation (hematoxylin and eosin staining, 100× magnification).
did not fulfill the ACR criteria (probably because
20% of the GCA patients have occult GCA). In
contrast, 28.3% of the patients met the criteria
but were biopsy negative. Ing et al developed
a new prediction model for diagnosing patients
with suspected GCA.[15] Their results are sim-
ilar to ours in terms of more positive biopsy
results in the elderly population as well as more
jaw claudication, more ischemic optic neuropathy,
and higher platelet levels, ESR, and CRP levels
206 JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 15, ISSUE 2, APRIL-JUNE 2020
Temporal Artery Biopsy for GCA; Abri Aghdam et al
Figure 2. GCA-positive temporal artery biopsy (H&E staining, 100× magnification). Note the narrowing of the arterial lumen and
infiltration of inflammatory cells andmultinucleated giant cells (asterisk) in addition to the destruction of the lamina elasticum (short
arrows). Age-related intramural calcification is also noted in this specimen (long arrow). GCA, giant cell arteritis; H&E, hematoxylin
and eosin.
in the positive biopsy group than in the neg-
ative biopsy group. They found these variables
significant predictors of positive TAB results. How-
ever, the 2016 rACR criteria has nine non-biopsy
items, which could permit greater differentiation
of patients with respect to the likelihood of a
positive TAB result and GCA diagnosis. Based
on the 2016 rACR criteria for the diagnosis of
GCA, Sait et al proposed a simple management
plan: (1) 2016 rACR scores ≤ 2 may not man-
date a biopsy as these patients are very unlikely
to have GCA; (2) patients with scores ≥ 5 will
also not need TAB as they are likely to have
GCA and should continue steroid therapy; and (3)
a biopsy will be required in cases with scores
of 3 and 4 because these patients have the
most variability in TAB results.[16] However, fur-
ther studies involving multiple centers with firm
inclusion criteria should be performed before an
algorithm that avoids biopsy in GCA management
is applied.
In our study, TAB-positive patients had a higher
mean overall rACR score than the TAB-negative
patients. One reason could be that TAB-positive
patients with compatible pathology accumulate
two more points in comparison with TAB-negative
patients. Sait et al compared the functional utility
of rACR criteria against the original ACR criteria
and found that the more extensive rACR can serve
as a more useful guide to reduce the number of
unnecessary biopsies.[16]
In case of TAB-positive results in the first and
second five years, the odds ratio was approxi-
mately 2.7 (comparing second five years to the
first five years), even though the P-value was
borderline. The increase in the specimen length
can be due to human factors. TABswere performed
by several different specialties in our center.
Some TABs were carried out by neurosurgery and
vascular surgery residents in the first five-year
interval, but the Department of Ophthalmology was
exclusively in charge of performing biopsies in the
second five-year interval. The ophthalmology team
was more experienced in the second five years
than in the first; however, our results indicated
that specimen length beyond a certain size did
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not influence the rate of positive results. The
proficiency of the pathology team may also play an
important role in analyzing specimens.
In recent years, other diagnostic modalities have
gained popularity because of their high specificity,
sensitivity, and ease of use. Color Doppler Ultra-
sound (CDUS) has been shown to have a specificity
of 78–100% and a sensitivity of 55–100% for
diagnosingGCA.[17] Although extensive experience
is needed for a proper diagnosis with CDUS, its
high resolution of 0.1 mm and its noninvasiveness
makes it a good choice as a diagnostic tool.
With CDUS, not only the temporal artery can be
visualized, but also other cranial arteries as well
as axillary and subclavian arteries can be visu-
alized for signs of vasculitis.[18–20] High-resolution
magnetic resonance imaging with magnetic reso-
nance angiography (MRA) has been reported to
have a pooled sensitivity of 73% and a specificity
of 88%. This modality can show the temporal
arteries and demonstrate mural edema if con-
trast is administered.[21] Other modalities, including
positron emission tomography (PET), computed
tomography (CT), CT with angiography, and con-
ventional MRA, lack sufficient spatial resolution
to permit visualization of the temporal artery and
hence are not the preferredmodalities in GCA. Due
to high fluorodeoxyglucose uptake in the brain,
PET scanning of cranial arteries is considerably
obscured.[22]
This study has several limitations. Because of
its retrospective nature, we encountered a con-
siderable amount of missing data that yielded a
lower sample size than we originally anticipated.
This might result in selection bias. Moreover, these
results do not illustrate the whole population, as
we included only patients from a tertiary referral
center. Despite these limitations, this is the first
study performed in Iran to evaluate the results of
TAB and the clinical and laboratory characteristics
of patients with suspected GCA.
In conclusion, we could not find an association
between the analysis of TABs and the clinical
evaluation of patients with GCA. Although TAB is
still considered the gold standard test for GCA
diagnosis, clinicians should consider both clinical
and pathological data to manage difficult cases.
This study shows that the majority of TABs are
negative, and reducing the number of redundant
biopsies is necessary to lower the workload of
medical staff and the use of medical services.
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